Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2014

01-01-2014 | Epidemiology

Breast cancer screening of women aged 70–74 years: results from a natural experiment across Australia

Authors: Carolyn Nickson, Kate E. Mason, Anne M. Kavanagh

Published in: Breast Cancer Research and Treatment | Issue 2/2014

Login to get access

Abstract

There is a lack of evidence regarding the optimal age at which to cease mammographic screening for breast cancer. This ecological study compared Australian state and territory level screening participation rates and cancer outcomes from 1996 to 2005 to identify the extent to which screening women aged 70–74 results in smaller, earlier stage breast cancers. With each 10 % absolute increase in screening participation, there was no significant difference in cancer incidence, but the incidence of large cancers was 8 % lower (IRR = 0.92, 95 % CI 0.90–0.94, p < 0.001); there was some evidence of reduced nodal involvement at diagnosis (IRR 0.97, 95 % CI 0.95–0.99, p = 0.004) but this estimate was sensitive to assumptions regarding missing data. Increased mammographic screening of women aged 70–74 years reduces the incidence of large (>15 mm) cancers—and possibly cancers with nodal involvement—without a concomitant increase in overall cancer incidence.
Appendix
Available only for authorised users
Literature
1.
International Agency for Research on Breast Cancer (2002) IARC handbooks of cancer prevention, vol 7: breast cancer screening. International Agency for Research on Breast Cancer, Lyon
2.
Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings SR (1999) Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. J Am Med Assoc 282(22):2156–2163CrossRef
3.
4.
Australian Institute of Health and Welfare (2009) Breast cancer in Australia: an overview, 2009 (Cat. no. CAN 46). Australian Institute of Health and Welfare, Canberra, October 2009. Report no.: Cancer series no. 50
5.
Australian Government Department of Health and Ageing (2009) Evaluation of the BreastScreen Australia program—evaluation final report. Australian Government Department of Health and Ageing, Canberra
6.
Australian Electoral Commission (2005) Australian Electoral Commission annual report 2004–05. Australian Electoral Commission, Canberra
7.
Australian Institute of Health and Welfare (2009) BreastScreen Australia monitoring report 2005–2006 (Cancer series no. 48. Cat. no. CAN 44). AIHW, Canberra
8.
9.
Department of Health and Ageing & Australian Institute of Health and Welfare (2008) BreastScreen Australia monitoring report 2004–2005 (Cancer Series no. 42. Cat no. 37), May 2008. Australian Institute of Health and Welfare, Canberra
10.
Australian Institute of Health and Welfare & National Breast Cancer Centre (2007) Breast cancer survival by size and nodal status in Australia. Australian Institute of Health and Welfare, Canberra
11.
BreastScreen Victoria (2012) BreastScreen Victoria annual statistical report, 2007. BreastScreen Victoria, Melbourne
12.
Australian Institute of Health and Welfare (2012) BreastScreen Australia monitoring report 2009–10 (Cancer series no. 72. Cat. no. CAN 68). AIHW, Canberra
13.
Australian Institute of Health and Welfare (2003) BreastScreen Australia monitoring report 1998–1999 and 1999–2000 (Cancer Series no. 26. Cat. no. CAN 21). Australian Institute of Health and Welfare, Canberra
14.
Australian Institute of Health & Welfare (2003) BreastScreen Australia monitoring report 2000–2001 (Cancer Series no. 25. Cat no. CAN 20). Australian Institute of Health and Welfare, Canberra
15.
Australian Institute of Health & Welfare (2005) BreastScreen Australia monitoring report 2001–2002 (Cancer Series no. 29. Cat no. CAN 24). Australian Institute of Health and Welfare, Canberra
16.
Australian Institute of Health & Welfare (2006) BreastScreen Australia monitoring report 2002–2003 (Cancer Series no. 32. Cat no. CAN 27). Australian Institute of Health and Welfare, Canberra
17.
Department of Health and Ageing & Australian Institute of Health and Welfare (2007) BreastScreen Australia monitoring report 2003–2004 (Cancer series no. 36. Cat. no. CAN 31). Australian Institute of Health and Welfare, Canberra
18.
Roder D, Houssami N, Farshid G, Gill G, Luke C, Downey P et al (2008) Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia. Breast Cancer Res Treat 108(3):409–416PubMedCrossRef
19.
Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A et al (1995) Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 75(10):2507–2517PubMedCrossRef
Metadata
Title
Breast cancer screening of women aged 70–74 years: results from a natural experiment across Australia
Authors
Carolyn Nickson
Kate E. Mason
Anne M. Kavanagh
Publication date
01-01-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2794-5

Other articles of this Issue 2/2014

Breast Cancer Research and Treatment 2/2014 Go to the issue

Epidemiology

Impact of full-field digital mammography on pre-operative diagnosis and surgical treatment of mammographic microcalcification

Brief Report

Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women

Preclinical study

Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells

Preclinical study

CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis

Preclinical Study

Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin

Preclinical Study

Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits